Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced new clinical data showing improvements in tardive dyskinesia symptoms and daily functioning among patients with intellectual and developmental disabilities treated with INGREZZA (valbenazine) capsules.

The analysis included 30 individuals with intellectual and developmental disabilities who had tardive dyskinesia. Nearly all patients experienced reductions in tardive dyskinesia symptoms, with 89% showing improvement within four weeks of starting treatment. The mean age of participants was 47.3 years, and 70% had moderate or severe tardive dyskinesia at baseline.

Clinicians reported that 90% of participants had functional impairments due to tardive dyskinesia before treatment. Following INGREZZA treatment, 96% of those with impaired function showed improvement in overall functional status. Specific improvements were noted in socializing with family and friends (92% of affected patients improved), dexterity (91%), emotions (85%), and independence (83%).

The data was presented at the American Academy of Developmental Medicine and Dentistry's 24th Annual Education Conference in Dallas. The analysis examined clinician-reported data from patients who initiated INGREZZA between January and June 2024 and completed at least two months of treatment.

"People with intellectual and developmental disabilities are at increased risk for tardive dyskinesia due to long-term antipsychotic use, yet the condition often goes underdiagnosed and its impact underrecognized," said Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences.

INGREZZA is FDA-approved for treating tardive dyskinesia in adults and chorea associated with Huntington's disease. The drug is a selective vesicular monoamine transporter 2 inhibitor that targets dopamine signaling in the brain.